Anchor Therapeutics' $10 Million Series B Fund May Grow Based On Near-Term Milestones
This article was originally published in The Pink Sheet Daily
Executive Summary
The platform company, which targets difficult to drug GPCRs, hopes to announce a Big Pharma collaboration soon, as well as project milestones that prove its worth.